SCHEMBL1011295

SCHEMBL1011295

Cc1ccc(Br)cc1Oc1ccc(C(F)(F)F)cn1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.56
HPGD P15428 1/20 0.52
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.47
POLB P06746 2/20 0.46
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 1/20 0.41
LIPE Q05469 4/20 0.41
MEN1 O00255 1/20 0.40
IDO1 P14902 1/20 0.39
GABRA5 P31644 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011521 0.83 KMT2A (0.66) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL8299427 0.80 HPGD (0.49) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL1009469 0.80 HPGD (0.49) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL5438816 0.77 THRB (0.60) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL9272113 0.76 THRB (0.76) THRBL3MBTL1KMT2AMAPTSMN1; SMN2
SCHEMBL31360442 0.76 TSHR (0.62) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL1013808 0.75 THRB (0.61) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL31360386 0.75 THRB (0.61) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL1417238 0.75 THRB (0.69) THRBL3MBTL1HPGDKMT2AMAPT
SCHEMBL1011398 0.74 THRB (0.72) THRBL3MBTL1HPGDKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101595102-B Diaryl ether urea compounds PFIZER PROD INC 2013-08-07 CN disclosed
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
CN-101595102-A Diaryl ether urea compounds PFIZER PROD INC (US) 2009-12-02 CN disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC THRB 2969/4885L3MBTL1 4652/4885HPGD 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.